PepEvolutionAOD-9604
A modified HGH fragment (176-191) for fat loss — the only one in its class to complete a phase-2b trial, which failed its primary endpoint.
Verdict — C · Emerging / Mixed
The rare gray-market peptide that actually completed a human RCT — and failed. A benign safety profile is not enough to offset a failed phase-2b endpoint. D-grade; gray-market versions add sourcing uncertainty on top of the weak efficacy case.
Overview
AOD-9604 is a modified form of HGH fragment 176-191 studied by Metabolic Pharmaceuticals (Australia) through a phase-2b obesity trial (METAOD006/METAOD008) that failed to demonstrate statistically significant weight loss vs placebo at 24 weeks. The compound has a benign safety profile, and gray-market availability is moderate. The failed trial is the defining data point: meaningful human evidence was sought and not found.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.